Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

BACKGROUND: Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunner, Hermine I, Foeldvari, Ivan, Alexeeva, Ekaterina, Ayaz, Nuray Aktay, Calvo Penades, Inmaculada, Kasapcopur, Ozgur, Chasnyk, Vyacheslav G, Hufnagel, Markus, Żuber, Zbigniew, Schulert, Grant, Ozen, Seza, Rakhimyanova, Adelina, Ramanan, Athimalaipet, Scott, Christiaan, Sozeri, Betul, Zholobova, Elena, Martin, Ruvie, Zhu, Xuan, Whelan, Sarah, Pricop, Luminita, Martini, Alberto, Lovell, Daniel, Ruperto, Nicolino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Paediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811076/
https://www.ncbi.nlm.nih.gov/pubmed/35961761
http://dx.doi.org/10.1136/ard-2022-222849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811076/
https://www.ncbi.nlm.nih.gov/pubmed/35961761
http://dx.doi.org/10.1136/ard-2022-222849

Ejemplares similares